- Prescribing Advice for GPs - https://www.prescriber.org.uk -


The MHRA have issued a press statement regarding the safety and efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs), specifically Paroxetine (Seroxat).

This press release is timed in response to media criticism aimed at regulatory authorities over the handling of the licensing and continued availability of Paroxetine.

In summary, the MHRA advice on the safe use of SSRIs is as follows:

Additionally, the MHRA specifically reviewed the safety of Venlafaxine (Efexor)